Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy.
FDG-PET/CT
anti-CD38
focal bone lesion
immunotherapy
myeloma
prognostic factor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Aug 2021
27 Aug 2021
Historique:
received:
30
06
2021
revised:
25
08
2021
accepted:
25
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated the predictive value of FDG PET/CT parameters for RRMM prior to initiating anti-CD38 treatment. We included 38 consecutive RRMM patients who underwent a PET/CT scan treated at our institution at relapse. The median PFS was 12.5 months and the median OS was not reached. 42% of the patients had an initial ISS score of 1, 37% of 2, and 21% of 3. The presence of >3 focal lesions (FLs,
Identifiants
pubmed: 34503133
pii: cancers13174323
doi: 10.3390/cancers13174323
pmc: PMC8431719
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2020 Jun 08;12(6):
pubmed: 32521788
Front Oncol. 2021 Mar 05;11:639528
pubmed: 33747963
Blood. 2005 Oct 1;106(7):2276-9
pubmed: 15961515
Leuk Lymphoma. 2019 Jan;60(1):222-225
pubmed: 29717914
J Clin Oncol. 2019 Jul 1;37(19):1657-1665
pubmed: 31091136
Biomed Pharmacother. 2012 Sep;66(6):448-53
pubmed: 22902054
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):493-500
pubmed: 22113619
Cancers (Basel). 2020 Aug 24;12(9):
pubmed: 32847053
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):116-128
pubmed: 30054697
Am J Hematol. 2020 Aug;95(8):966-977
pubmed: 32350883
Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719
pubmed: 29270787
J Clin Oncol. 2017 Sep 1;35(25):2911-2918
pubmed: 28686535
Lancet Oncol. 2019 Jun;20(6):e302-e312
pubmed: 31162104
AJR Am J Roentgenol. 2005 Apr;184(4):1199-204
pubmed: 15788594
Hematology. 2021 Dec;26(1):510-517
pubmed: 34314294
Eur J Haematol. 2011 Apr;86(4):289-98
pubmed: 21198866
Blood. 2009 Sep 3;114(10):2068-76
pubmed: 19443657
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
Br J Haematol. 2021 May;193(3):542-550
pubmed: 33792026
J Nucl Med. 2002 Nov;43(11):1457-63
pubmed: 12411548
Cancers (Basel). 2020 Sep 06;12(9):
pubmed: 32899991
Leukemia. 2021 Jul 10;:
pubmed: 34247197
Lancet Oncol. 2017 Apr;18(4):e206-e217
pubmed: 28368259
Clin Cancer Res. 2017 Apr 15;23(8):1981-1987
pubmed: 27698001
Oncotarget. 2014 Sep 15;5(17):7381-91
pubmed: 25277179
Cancers (Basel). 2021 Apr 16;13(8):
pubmed: 33923781
Haematologica. 2007 Jan;92(1):50-5
pubmed: 17229635
Blood. 2017 Aug 24;130(8):974-981
pubmed: 28637662
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Clin Nucl Med. 2009 Sep;34(9):576-84
pubmed: 19692817
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Blood. 2011 Dec 1;118(23):5989-95
pubmed: 21900189
Haematologica. 2017 Mar;102(3):e104-e107
pubmed: 27909220
J Clin Oncol. 2021 Jan 10;39(2):116-125
pubmed: 33151787